CS
PSTV

Credit Suisse’s Plus Therapeutics PSTV Stock Holding History

Credit Suisse’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-30
Closed -$38K – 4295
2019
Q3 		$38K Buy
+30
New +$108K ﹤0.01% 4062
2015
Q3 		– Hold
0
– -$75K – 4436
2015
Q2 		– Hold
0
– – – 4423
2015
Q1 		– Hold
0
– – – 4321
2014
Q4 		– Hold
0
– – – 4517
2014
Q3 		– Hold
0
– – – 4403
2014
Q2 		– Hold
0
– – – 4490
2014
Q1 		– Hold
0
– – – 4509
2013
Q4 		– Hold
0
– – – 4468
2013
Q3 		– Hold
0
– – – 4141
2013
Q2 		– Hold
0
– – – 4116

Other funds holding PSTV

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
EGM
Engineers Gate Manager New York $8B AUM 17.32% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Credit Suisse's PSTV Position: Q4 2019 in Review

Credit Suisse sold out of Plus Therapeutics (PSTV) in Q4 2019, closing a stake of 30 shares — an estimated $38K sold.

Credit Suisse first reported a position in PSTV in Q3 2019 and held it in 1 quarter. The position peaked at $38K in Q3 2019. 9 funds tracked by Wall St. Rank hold PSTV as of Q4 2019.

  • Credit Suisse reported no remaining Plus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Credit Suisse sold 30 Plus Therapeutics shares in Q4 2019, an estimated $38K.
  • Credit Suisse first reported a position in Plus Therapeutics in Q3 2019 and held it in 1 quarter.
  • Credit Suisse's Plus Therapeutics position peaked at $38K in Q3 2019.
  • 9 funds tracked by Wall St. Rank held Plus Therapeutics as of Q4 2019.

Based on Credit Suisse's 13F filing for Q4 2019, filed 12 Feb 2020.